{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Estradiol", "query": { "intervention": "Continuous Estradiol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 94, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Estradiol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-25T17:35:52.926Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03179904", "title": "TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Breast Carcinoma", "HER2-Positive Breast Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Denifanstat", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-08-03", "completion_date": "2026-03-13", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179904" }, { "nct_id": "NCT01669291", "title": "Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fertility" ], "interventions": [ { "name": "Bravelle and Menopur", "type": "DRUG" }, { "name": "Agonist", "type": "DRUG" }, { "name": "Antagonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Main Line Fertility Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "21 Years to 40 Years · Female only" }, "enrollment_count": 43, "start_date": "2012-07", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 1, "location_summary": "Bryn Mawr, Pennsylvania", "locations": [ { "city": "Bryn Mawr", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01669291" }, { "nct_id": "NCT04856306", "title": "Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heavy Menstrual Bleeding", "Fibroid Uterus" ], "interventions": [ { "name": "Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure", "type": "OTHER" }, { "name": "Elagolix Oral Product", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Medstar Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 300, "start_date": "2021-04-12", "completion_date": "2025-08-30", "has_results": false, "last_update_posted_date": "2022-05-05", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04856306" }, { "nct_id": "NCT00161681", "title": "Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Premenstrual Syndrome" ], "interventions": [ { "name": "Levonorgestrel/Ethinyl Estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 200, "start_date": "2005-07", "completion_date": "2006-08", "has_results": false, "last_update_posted_date": "2013-02-08", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 48, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 40 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00161681" }, { "nct_id": "NCT02137837", "title": "S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Placebo - Anastrozole", "type": "DRUG" }, { "name": "Placebo - Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2014-05", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2021-01-28", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 223, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02137837" }, { "nct_id": "NCT00001521", "title": "Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Congenital Adrenal Hyperplasia (CAH)" ], "interventions": [ { "name": "Fludrocortisone", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Flutamide", "type": "DRUG" }, { "name": "Testolactone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 66, "start_date": "1995-06-08", "completion_date": "2024-04-01", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001521" }, { "nct_id": "NCT03236545", "title": "Menopause Effects on Vascular Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Risk Factor" ], "interventions": [ { "name": "No to Low Endogenous Estrogen", "type": "OTHER" }, { "name": "Estradiol", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Delaware", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 48, "start_date": "2016-07-01", "completion_date": "2022-11-01", "has_results": false, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 1, "location_summary": "Newark, Delaware", "locations": [ { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03236545" }, { "nct_id": "NCT00176644", "title": "Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Transdermal Estradiol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 23, "start_date": "2005-05", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 6, "location_summary": "Freehold, New Jersey • Hamilton, New Jersey • Morristown, New Jersey + 2 more", "locations": [ { "city": "Freehold", "state": "New Jersey" }, { "city": "Hamilton", "state": "New Jersey" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00176644" }, { "nct_id": "NCT05654623", "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Breast Cancer" ], "interventions": [ { "name": "ARV-471", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 624, "start_date": "2023-03-03", "completion_date": "2028-05-15", "has_results": true, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 87, "location_summary": "Encinitas, California • Fountain Valley, California • Fresno, California + 69 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Napa", "state": "California" }, { "city": "San Marcos", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05654623" }, { "nct_id": "NCT05505162", "title": "Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Female Participants" ], "interventions": [ { "name": "Zibotentan", "type": "DRUG" }, { "name": "EE/LNG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "35 Years to 75 Years · Female only" }, "enrollment_count": 24, "start_date": "2022-08-24", "completion_date": "2023-01-10", "has_results": false, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-09-25T17:35:52.926Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05505162" } ] }